Role of Liraglutide in improving diabetes and suppressing appetite in Biedl-Bardet syndrome

Abstract

Biedl-Bardet syndrome (BBS) is a rare autosomal recessive disorder that is characterized by severe abdominal obesity, intellectual disability, polydactyly, male hypogonadism, visual impairment and functional or structural abnormalities of the kidneys. Traditionally, lifestyle changes and bariatric surgery has been used to manage obesity in Biedl-Bardet syndrome while oral hypoglycemic agents and insulin has been used for management of diabetes. Recently, Setmelanotide has been approved for management of chronic weight management in adults and children more than 6 years old with Biedl-Bardet syndrome. We report the case of an adolescent male with BBS who was initiated on liraglutide not only to manage his diabetes but also to suppress his appetite, thus helping in weight loss. To the best of our knowledge, this case is one of the few successful uses of a glucagon like peptide-1(GLP-1) agonist in an adolescent male with Biedl-Bardet syndrome and type 2 diabetes mellitus with the aim of controlling his hyperphagia as well as his diabetes.

How to cite this: Qayyum A, Ali A, Raja UY. Role of Liraglutide in improving diabetes and suppressing appetite in Biedl-Bardet syndrome. JPES. 2024;1(1):34-36.